Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
复制标题
DOI：
10.1016/j.oraloncology.2009.09.002
复制
发表时间：
2009-12
期刊：
影响因子：
4.8
通讯作者：
Kengo Saito;H. Shirasawa;N. Isegawa;M. Shiiba;K. Uzawa;H. Tanzawa
中科院分区：
文献类型：
--
作者：
Kengo Saito;H. Shirasawa;N. Isegawa;M. Shiiba;K. Uzawa;H. Tanzawa
溶瘤病毒疗法使用的病毒可以选择性地摧毁癌细胞，而不会损害正常组织。溶瘤病毒的临床试验表明，大多数溶瘤药物耐受性良好且安全。目前使用的病毒治疗药物单独使用时效力有限；然而，使用病毒治疗药物和常规抗癌药物的联合治疗，如化疗、放射治疗和基因治疗，显示出令人鼓舞的疗效水平。重组DNA技术的进步使具有肿瘤选择性和携带转基因的病毒的发展成为可能，增加了这种新型抗癌疗法的应用潜力和疗效。本文就溶瘤病毒的研究进展和溶瘤病毒治疗口腔癌的临床试验作一综述。我们讨论了这种不断发展的抗癌疗法的当前问题和前景，强调了一种独特的、自然发生的溶瘤病毒-辛德比斯病毒的潜在应用。
Oncolytic virotherapy utilizes viruses that can selectively destroy cancer cells without harming normal tissues. Clinical trials of oncolytic viruses show that most oncolytic agents are well tolerated and safe. The virotherapeutic agents currently in use have limited potency when administered alone; however, combination therapy using virotherapeutic agents and conventional anticancer agents, such as chemotherapeutics, radiation, and gene therapy, exhibits encouraging levels of efficacy. Advances in recombinant DNA technology have allowed the development of viruses that are tumor-selective and armed with transgenes, increasing the application potential and efficacy of this novel anticancer therapy. Here, we reviewed the development of oncolytic viruses and the clinical trials of oncolytic virotherapy for oral cancers. We discuss current issues and perspectives of this evolving anticancer therapy, highlighting the potential applications of a unique, naturally occurring oncolytic virus, Sindbis virus.